These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 27646474)

  • 41. Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for anti-glioblastoma treatment.
    Kang T; Zhu Q; Jiang D; Feng X; Feng J; Jiang T; Yao J; Jing Y; Song Q; Jiang X; Gao X; Chen J
    Biomaterials; 2016 Sep; 101():60-75. PubMed ID: 27267628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted delivery of nano-PTX to the brain tumor-associated macrophages.
    Zou L; Tao Y; Payne G; Do L; Thomas T; Rodriguez J; Dou H
    Oncotarget; 2017 Jan; 8(4):6564-6578. PubMed ID: 28036254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
    Hu C; Huang Y; Chen Y
    Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma.
    Zhang B; Sun X; Mei H; Wang Y; Liao Z; Chen J; Zhang Q; Hu Y; Pang Z; Jiang X
    Biomaterials; 2013 Dec; 34(36):9171-82. PubMed ID: 24008043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Novel Strategy through Combining iRGD Peptide with Tumor-Microenvironment-Responsive and Multistage Nanoparticles for Deep Tumor Penetration.
    Cun X; Chen J; Ruan S; Zhang L; Wan J; He Q; Gao H
    ACS Appl Mater Interfaces; 2015 Dec; 7(49):27458-66. PubMed ID: 26633260
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas.
    Su Z; Xing L; Chen Y; Xu Y; Yang F; Zhang C; Ping Q; Xiao Y
    Mol Pharm; 2014 Jun; 11(6):1823-34. PubMed ID: 24779677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
    Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
    Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. iRGD and TGN co-modified PAMAM for multi-targeted delivery of ATO to gliomas.
    Shi X; Ma R; Lu Y; Cheng Y; Fan X; Zou J; Zheng H; Li F; Piao JG
    Biochem Biophys Res Commun; 2020 Jun; 527(1):117-123. PubMed ID: 32446354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
    Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
    Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
    Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
    Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care.
    Yi S; Yang F; Jie C; Zhang G
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3438-3447. PubMed ID: 31411066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Asn-Gly-Arg-modified polydopamine-coated nanoparticles for dual-targeting therapy of brain glioma in rats.
    Hu J; Zhang X; Wen Z; Tan Y; Huang N; Cheng S; Zheng H; Cheng Y
    Oncotarget; 2016 Nov; 7(45):73681-73696. PubMed ID: 27655664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined integrin α
    Qi N; Zhang S; Zhou X; Duan W; Gao D; Feng J; Li A
    J Nanobiotechnology; 2021 Dec; 19(1):446. PubMed ID: 34949198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma.
    Householder KT; DiPerna DM; Chung EP; Wohlleb GM; Dhruv HD; Berens ME; Sirianni RW
    Int J Pharm; 2015 Feb; 479(2):374-80. PubMed ID: 25562639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
    Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
    Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
    Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
    Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy.
    Miao D; Jiang M; Liu Z; Gu G; Hu Q; Kang T; Song Q; Yao L; Li W; Gao X; Sun M; Chen J
    Mol Pharm; 2014 Jan; 11(1):90-101. PubMed ID: 24295590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
    Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
    J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.
    Kuang Y; An S; Guo Y; Huang S; Shao K; Liu Y; Li J; Ma H; Jiang C
    Int J Pharm; 2013 Sep; 454(1):11-20. PubMed ID: 23867728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. nRGD modified lycobetaine and octreotide combination delivery system to overcome multiple barriers and enhance anti-glioma efficacy.
    Chen T; Song X; Gong T; Fu Y; Yang L; Zhang Z; Gong T
    Colloids Surf B Biointerfaces; 2017 Aug; 156():330-339. PubMed ID: 28544965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.